'Life changing' blood cancer drugs approved by NHS for aggressive form of disease
Aileen Lamb, from Edinburgh who had acute myeloid leukaemia said the approval of the new drug gives sufferers hope.
Pharmabiz9h
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
Alteogen Enters Into An Exclusive License Agreement To Develop And Commercialize Subcutaneous ENHERTU® Enabled By Alteogen's Hybrozymetm Technology
ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...
Alteogen Enters License Deal With Daiichi Sankyo For ALT-B4 In Subcutaneous ENHERTU Development
Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...
Le Lézard11h
'From Chancay to Shanghai': A revelation of the times: Global Times editorial
During the 31st APEC Economic Leaders' Meeting in Lima, Peru, this week, a milestone will be reached - the Chancay Port, controlled and invested by Chinese enterprises, is set to hold its operation ...